

## **Transfer of Marketing Authorizations and Distribution Rights for Bone Metabolism Marker “OSTEOMARK” and “OSTEOMARK NTx SERUM”**

---

Inverness Medical Japan Co., Ltd.  
Mochida Pharmaceutical Co., Ltd.

(Tokyo, March 3, 2008) - Inverness Medical Japan Co., Ltd. (IMJ) (Headquarters: Shinjuku-ku, Tokyo; President: Kiyonori Karasawa) and Mochida Pharmaceutical Co., Ltd. (Mochida) (Headquarters: Shinjuku-ku, Tokyo; President: Naoyuki Mochida) have agreed to transfer the marketing authorizations and the distribution rights for *in vitro* diagnostic products to determine NTx in urine “OSTEOMARK” and NTx in serum “OSTEOMARK NTx Serum” sold by Mochida in Japan to IMJ as of April 1, 2008. Following this agreement, IMJ will start selling “OSTEOMARK” and “OSTEOMARK NTx Serum” as from April 1.

“OSTEOMARK” and “OSTEOMARK NTx Serum” are *in vitro* diagnostics used as indicators for monitoring of osteoporosis treatment by measuring Cross-linked N-telopeptides of Type I Collagen (NTx) in urine and serum.

Mochida has imported those products from a group company of Inverness Medical Innovations, Inc. (IMI) (Headquarters: Massachusetts, US) and distributed them in Japan. Following this agreement, IMJ which is a Japanese subsidiary of IMI will take over the import, distribution and promotion activities.